Gilead Agrees to Buy PepStar Oral IL-23 Receptor Program
Source-gap reconciliation: Gilead’s 22 October 2026 agreement to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program was absent from the prior-day report set. The price is $1.275 billion upfront cash at closing, subject to…
